Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brensocatib - Insmed

Next Previous
Search
Drug Profile

Brensocatib - Insmed

Alternative Names: AZD 7986; INS-1007

Latest Information Update: 24 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Insmed
  • Class Amides; Anti-inflammatories; Antibronchitics; Benzoxazoles; Nitriles; Oxazepines; Skin disorder therapies; Small molecules
  • Mechanism of Action Dipeptidyl peptidase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Bronchiectasis
  • Phase II Hidradenitis suppurativa; Rhinosinusitis
  • Discontinued Chronic obstructive pulmonary disease; COVID 2019 infections; Cystic fibrosis; Granulomatosis with polyangiitis

Most Recent Events

  • 20 Feb 2025 Insmed has patent protection as well as pending patents for Brensocatib in USA, China, Europe and Japan
  • 06 Feb 2025 Brensocatib receives priority review status for Bronchiectasis in USFDA
  • 06 Feb 2025 FDA assigns PDUFA action date of (12/08/2025) for Brensocatib for Bronchiectasis (In adolescents, In adults, In the elderly, Non-cystic fibrosis-related)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top